Day One Highlights Transformational 2025 and OJEMDA Growth

The latest announcement is out from Day One Biopharmaceuticals ( (DAWN) ).

Day One Biopharmaceuticals reported on Feb. 24, 2026 that 2025 was a transformational year, driven by strong commercial uptake of its pediatric cancer drug OJEMDA and a broadened oncology pipeline following the January 2026 acquisition of Mersana Therapeutics. OJEMDA generated net product revenue of $52.8 million in the fourth quarter and $155.4 million for full year 2025, representing 172% year-over-year growth and sharp gains in prescription volumes, while the company reaffirmed its 2026 U.S. revenue guidance of $225 million to $250 million.

Clinically, updated three-year FIREFLY-1 data presented in November 2025 underscored the durability and safety of OJEMDA in relapsed or refractory pLGG, and enrollment in the pivotal frontline FIREFLY-2 Phase 3 trial is expected to complete in the first half of 2026. Financially, Day One narrowed its 2025 net loss to $107.3 million on reduced R&D spending and ended the year with $441.1 million in cash and investments, positioning it to advance Phase 1 programs for Emi-Le and DAY301 while maintaining an active presence at upcoming healthcare investor conferences.

The company’s strengthened balance sheet, accelerating OJEMDA franchise, and expanded ADC portfolio underscore its bid to cement a leading position in targeted therapies for rare and pediatric cancers. Stakeholders will closely watch 2026 clinical readouts for Emi-Le and DAY301, alongside completion of FIREFLY-2 enrollment, as key catalysts for Day One’s medium-term growth trajectory.

The most recent analyst rating on (DAWN) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Day One Biopharmaceuticals stock, see the DAWN Stock Forecast page.

Spark’s Take on DAWN Stock

According to Spark, TipRanks’ AI Analyst, DAWN is a Neutral.

The score is driven by strong technical momentum and upbeat business momentum (raised guidance and strong OJEMDA prescription/revenue trends), supported by a low-leverage balance sheet. Offsetting these positives are continued operating losses, substantial cash burn, and limited valuation support due to negative earnings.

To see Spark’s full report on DAWN stock, click here.

More about Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc., based in Brisbane, Calif., is a commercial-stage biopharmaceutical company focused on developing and commercializing targeted cancer therapies for patients of all ages, with a particular emphasis on pediatric oncology and other rare cancers. Its pipeline includes the RAF inhibitor tovorafenib (marketed as OJEMDA), the PTK7-targeted antibody-drug conjugate DAY301, and Emi-Le, a B7-H4-directed antibody-drug conjugate acquired with Mersana Therapeutics to treat adenoid cystic carcinoma.

Average Trading Volume: 2,571,960

Technical Sentiment Signal: Buy

Current Market Cap: $1.22B

Learn more about DAWN stock on TipRanks’ Stock Analysis page.